This Virtual Preceptorship invites learners to explore the mechanisms of bispecific antibodies in the management of relapsed/refractory multiple myeloma. Novel bispecific antibodies simultaneously target CD3 on immune T cells and a target on malignant B cells, such as BCMA. By guiding T cells to malignant myeloma cells, bispecific antibodies enable the precise immune attack of malignant cells. In the process of immune attack, bispecific antibodies may trigger adverse events that require careful monitoring and multidisciplinary management. In this virtual reality program, clinicians will gain perspectives on both mechanisms and safe use of bispecific antibodies in patients with relapsed/refractory multiple myeloma.

RELEASED DATE: January 24, 2024
EXPIRATION DATE: January 24, 2025

Through this virtual preceptorship program, learners will evaluate current and emerging applications of bispecific antibodies in the management of non-Hodgkin lymphoma, as informed by the latest data. With multiple novel bispecific antibodies targeting CD20 on malignant B cells and CD3 on immune effector T cells, there is an increasing need for awareness of the efficacy, safety, and best practices for use of these therapies in relapsed and refractory forms of non-Hodgkin lymphomas. In addition to recognizing clinical data and mechanisms, this program discusses potential adverse events associated with bispecific antibody therapies and best practices for their monitoring and management. This unique program enables clinicians to understand the design, mechanisms, and safety and efficacy data informing the integration of bispecific antibodies in management of non-Hodgkin lymphomas.

RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025

This interactive enduring activity is designed to help you optimize the development of treatment plans for your patients with advanced melanoma. Specifically, this program will provide a comprehensive review of the latest data on current and emerging immunotherapy approaches, and of effective strategies to mitigate and manage immunotherapy-associated adverse events. It will also share, expert appraisals of new treatment approaches through multiple clinical case scenarios, illustrative animations, and didactic presentations. Our goal is also to emphasize the importance of shared decision making while maintaining the patient’s well-being.

RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025

This Grand Rounds program will help you understand the biology of TROP2 in breast cancer; examine the rationale for use of TROP2-directed antibody-drug conjugates (ADCs) in breast cancer; recognize adverse effects most commonly associated with ADCs and best practices for their prevention, mitigation, and management; and formulate strategies for integrating TROP2-directed ADCs into breast cancer treatment algorithms. This interactive program combines didactic instruction with case-based discussions and illustrative animations.

RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025

Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025

This enduring is designed to assist veterans’ affairs-associated members of the multi-disciplinary oncology care team in evaluating current developments in the use of novel bispecific antibody therapies in later-line management of Non-Hodgkin’s Lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and current efficacy and safety data associated with adverse event management in NHL.

RELEASED DATE: January 18, 2024
EXPIRATION DATE: January 18, 2025

This enduring activity is designed to meet the educational needs of healthcare practitioners to ensure confidence in the management of patients with HER3-overexpressing lung cancer. The program will address the biologic and clinical aspects of HER3 in advanced and EGFR-resistant NSCLC, and present the latest clinical trial data from current and ongoing trials of HER3-targeted antibodies in the management of NSCLC. The program will also evaluate the roles of multidisciplinary team members in the monitoring and management of treatment-related adverse events associated with HER3-targeted therapies.

RELEASED DATE: December 12, 2024
EXPIRATION DATE: December 12, 2025

With multiple immunotherapy treatment options and combinations available for the management of advanced melanoma, clinicians require updates in the application of clinical data to guide shared decision-making and multidisciplinary care. In this concise program, Dr. Adil Daud reviews current evidence-based guidelines, clinical data informing treatment decisions, and demonstrates best practices for application of data in patients with advanced melanoma.

RELEASED DATE: July 24, 2024
EXPIRATION DATE: July 24, 2025

These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.

RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024

Aimed toward U.S. community-based oncology care providers who serve patients with melanoma, this educational program will inform on the emerging role of adjuvant immunotherapy in patients who have undergone surgical resection for Stage IIB/C melanoma, and help practitioners integrate these treatment options in their patient care plan. This TeleECHO series will also provide guidance on identifying and mitigating immune-related adverse events in patients with early-stage melanoma receiving immunotherapy.

RELEASED DATE: April 12, 2024
EXPIRATION DATE: April 12, 2025